Literature DB >> 1331509

Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.

L H Nguyen1, D M Knipe, R W Finberg.   

Abstract

Live viruses and live virus vaccines induce cellular immunity more readily than do inactivated viruses or purified proteins, but the mechanism by which this process occurs is unknown. A trivial explanation would relate to the ability of live viruses to spread and infect more cells than can inactivated virus. We have used live but replication-defective mutants to investigate this question. Our studies indicate that the immune responses of mice to live virus differ greatly from the responses to inactivated virus even when the virus does not complete a replicative cycle. Further, these studies indicate that herpes simplex virus-specific T-cell responses can be generated by infection with replication-defective mutant viruses. These data indicate that the magnitude of the cellular immunity to herpes simplex virus may be proportional to the number or quantity of different viral gene products expressed by an immunizing virus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331509      PMCID: PMC240374     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine.

Authors:  E B Gurvich
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides.

Authors:  R W Honess; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

3.  Risks of smallpox vaccination complications in the United States.

Authors:  J M Lane; J D Millar
Journal:  Am J Epidemiol       Date:  1971-04       Impact factor: 4.897

4.  The intranuclear location of a herpes simplex virus DNA-binding protein is determined by the status of viral DNA replication.

Authors:  M P Quinlan; L B Chen; D M Knipe
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

5.  Replication of herpes simplex virus in human T lymphocytes: characterization of the viral target cell.

Authors:  R W Braun; H K Teute; H Kirchner; K Munk
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

6.  Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0.

Authors:  S Martin; X X Zhu; S J Silverstein; R J Courtney; F Yao; F J Jenkins; B T Rouse
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

7.  Cytotoxic T lymphocytes specific for herpes simplex virus (HSV) studied using adenovirus vectors expressing HSV glycoproteins.

Authors:  L A Witmer; K L Rosenthal; F L Graham; H M Friedman; A Yee; D C Johnson
Journal:  J Gen Virol       Date:  1990-02       Impact factor: 3.891

8.  Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize immediate-early protein ICP27.

Authors:  T A Banks; E M Allen; S Dasgupta; R Sandri-Goldin; B T Rouse
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

9.  Replication-defective viruses modulate immune responses.

Authors:  M J Browning; B S Huneycutt; A S Huang; C S Reiss
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

10.  Cell-mediated immunity against herpes simplex induction of cytotoxic T lymphocytes.

Authors:  M J Lawman; B T Rouse; R J Courtney; R D Walker
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

View more
  28 in total

1.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.

Authors:  X J Da Costa; C A Jones; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 5.  Recent advances in vaccine development for herpes simplex virus types I and II.

Authors:  Jeffrey L Coleman; Deepak Shukla
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

Review 6.  The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors.

Authors:  B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Viral replication is required for induction of ocular immunopathology by herpes simplex virus.

Authors:  J S Babu; J Thomas; S Kanangat; L A Morrison; D M Knipe; B T Rouse
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 8.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

9.  Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.

Authors:  Richard Brans; Natali V Akhrameyeva; Feng Yao
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

10.  The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.

Authors:  Hanka Augustinova; Daniela Hoeller; Feng Yao
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.